Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process
Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a...
Saved in:
Published in | Pharmaceutics Vol. 16; no. 11; p. 1471 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
MDPI AG
01.11.2024
MDPI |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as “liquid” cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that “liquid” cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, “liquid” cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of “liquid” cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that “liquid” cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the “liquid” cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms. |
---|---|
AbstractList | The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability.
In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as "liquid" cisplatin.
Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that "liquid" cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, "liquid" cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of "liquid" cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that "liquid" cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin.
Aqueous cisplatin solubility was increased by 27X in the "liquid" cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms. Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as "liquid" cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that "liquid" cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, "liquid" cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of "liquid" cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that "liquid" cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the "liquid" cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms.Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as "liquid" cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that "liquid" cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, "liquid" cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of "liquid" cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that "liquid" cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the "liquid" cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms. Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as “liquid” cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that “liquid” cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, “liquid” cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of “liquid” cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that “liquid” cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the “liquid” cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms. Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility and storage stability. Method: In this context, we report the use of a customized RESS process for the synthesis of a novel, amber-colored and viscous aqueous cisplatin solution, an important anticancer drug, which we have denoted as “liquid” cisplatin. Results: Using specialized liquid cell in situ transmission electron microscopy (Liquid in situ TEM) and Raman spectroscopy, we demonstrated that “liquid” cisplatin comprises a bi-modal distribution of a highly solvated network of stable cisplatin nanoclusters in water and exhibited 27 times greater water solubility than standard cisplatin. More importantly, “liquid” cisplatin was stable at ambient conditions for over two years. Extensive analytical characterization of “liquid” cisplatin confirmed that it retained the original chemical identity of cisplatin. Cell viability and apoptosis studies on human lung adenocarcinoma A549 cells provided compelling evidence that “liquid” cisplatin demonstrated a more sustained anticancer effect compared to standard cisplatin. Conclusions: Aqueous cisplatin solubility was increased by 27X in the “liquid” cisplatin medium which retained its bio efficacy over a 2-year period. Our experimental results suggest the possibility of developing non-invasive and highly effective novel cisplatin drug-delivery platforms. |
Audience | Academic |
Author | Prakasam, Thirumurugan Palanikumar, Loganathan Jagannathan, Ramesh Sharma, Sudhir Kumar Pasricha, Renu Magzoub, Mazin |
AuthorAffiliation | 3 Retired from Core Technology Platform, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; renu1505@gmail.com 1 Engineering Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; sks16@nyu.edu 4 Science Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; tp42@nyu.edu 2 Biology Program, Division of Science, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; pl105@nyu.edu (L.P.); mm6432@nyu.edu (M.M.) |
AuthorAffiliation_xml | – name: 2 Biology Program, Division of Science, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; pl105@nyu.edu (L.P.); mm6432@nyu.edu (M.M.) – name: 3 Retired from Core Technology Platform, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; renu1505@gmail.com – name: 4 Science Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; tp42@nyu.edu – name: 1 Engineering Division, New York University Abu Dhabi, Abu Dhabi P.O. Box 129188, United Arab Emirates; sks16@nyu.edu |
Author_xml | – sequence: 1 givenname: Sudhir Kumar surname: Sharma fullname: Sharma, Sudhir Kumar – sequence: 2 givenname: Loganathan surname: Palanikumar fullname: Palanikumar, Loganathan – sequence: 3 givenname: Renu surname: Pasricha fullname: Pasricha, Renu – sequence: 4 givenname: Thirumurugan orcidid: 0000-0003-3450-6328 surname: Prakasam fullname: Prakasam, Thirumurugan – sequence: 5 givenname: Mazin orcidid: 0000-0003-3414-6617 surname: Magzoub fullname: Magzoub, Mazin – sequence: 6 givenname: Ramesh orcidid: 0000-0003-0269-6446 surname: Jagannathan fullname: Jagannathan, Ramesh |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39598594$$D View this record in MEDLINE/PubMed |
BookMark | eNptkltvFCEUgImpsRf7EzST-OLLVhhgBp7MZlNrY6PGtc8EmMMumxlYYcak_162W2vXFB64fecj5-ScoqMQAyD0huALSiX-sF3rNGgL0-htJg0hhLXkBTohUsoZkzU9erI_Ruc5b3AZlBJB5St0TCWXgkt2gr4s78K4huxzFV21hN7N5jnDYHroqq86xDymyY5TKseFz9tejz5Ut9mHVVXiqh-Xy2X1PUULOb9GL53uM5w_rGfo9tPlz8Xn2c23q-vF_GZmeU3GmdZdJ7jATeOMtqxlrcOUa8lb6nSrNSW8rS0Fo7npnHG1NM7xxkoJzgBgeoau994u6o3aJj_odKei9ur-IqaV0qlUpgcFxUsayqwFxiwRBhOKO8MlcC4c7orr4961ncwAnYUwJt0fSA9fgl-rVfytCOGybbkshvcPhhR_TZBHNfhsoe91gDhlRQmljEvc8IK--w_dxCmFUqt7qm5kU4t_1EqXDHxwsXxsd1I1F0SwRhCyoy6eocrsYPC2tIvz5f4g4O3TTB9T_NsLBeB7wKaYcwL3iBCsdm2nnm07-gfHF82w |
Cites_doi | 10.1182/blood.V84.5.1415.bloodjournal8451415 10.1016/j.supflu.2015.11.019 10.1038/s41467-021-23985-1 10.1002/ijc.33588 10.1074/jbc.M109.026583 10.1111/cbdd.12786 10.1021/acsomega.7b00688 10.5114/wo.2012.31775 10.3322/caac.21763 10.1039/C9NA00684B 10.1038/377580a0 10.1200/JCO.2011.39.1110 10.1038/nrc2167 10.1002/9780470405840 10.1080/01926230701320337 10.4103/0253-7613.157132 10.1016/S0960-894X(01)81162-8 10.1016/j.phrs.2016.01.001 10.3322/caac.21731 10.1021/acs.biochem.0c00141 10.1016/S0896-8446(01)00064-X 10.1038/s42003-020-0817-4 10.1016/j.jddst.2022.103928 10.1126/science.6890712 10.1021/acsomega.9b03917 10.1006/abbi.1993.1311 10.1186/s40780-020-00163-x 10.1007/s00374-014-0940-9 10.1016/j.bioorg.2019.102925 10.1021/acsnano.3c04564 10.1016/j.ejphar.2014.07.025 10.1016/j.jinorgbio.2015.09.002 10.1016/j.apsusc.2013.05.159 10.1021/acs.jpca.8b04023 10.1007/s11095-013-1134-0 10.3892/or.2013.2279 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2024 MDPI AG 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2024 by the authors. 2024 |
Copyright_xml | – notice: COPYRIGHT 2024 MDPI AG – notice: 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2024 by the authors. 2024 |
DBID | AAYXX CITATION NPM 3V. 7XB 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO GNUQQ GUQSH M2O MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA |
DOI | 10.3390/pharmaceutics16111471 |
DatabaseName | CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One Community College ProQuest Central ProQuest Central Student ProQuest Research Library Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | PubMed MEDLINE - Academic Publicly Available Content Database CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1999-4923 |
ExternalDocumentID | oai_doaj_org_article_e5a91634cce44c18b0130db59e558f0d PMC11597759 A818468118 39598594 10_3390_pharmaceutics16111471 |
Genre | Journal Article |
GeographicLocations | United States United Arab Emirates |
GeographicLocations_xml | – name: United Arab Emirates – name: United States |
GrantInformation_xml | – fundername: NYU Abu Dhabi grantid: AD008; AD389 |
GroupedDBID | --- 53G 5VS 8G5 AADQD AAYXX ABDBF ABUWG ACGFO ACIHN ACUHS AEAQA AFKRA AFZYC ALMA_UNASSIGNED_HOLDINGS AZQEC BENPR BPHCQ CCPQU CITATION DIK DWQXO EBD ESX F5P FD6 GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IAO IHR ITC KQ8 M2O M48 MK0 MODMG M~E OK1 P6G PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RNS RPM TR2 TUS 3V. NPM PMFND 7XB 8FK MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 5PM PUEGO |
ID | FETCH-LOGICAL-c521t-aadd858066fbac4747f035a9573fa7aa31572c3eba5bdfbf29bff56c99efbee03 |
IEDL.DBID | M48 |
ISSN | 1999-4923 |
IngestDate | Wed Aug 27 01:32:15 EDT 2025 Thu Aug 21 18:34:57 EDT 2025 Fri Jul 11 05:12:58 EDT 2025 Mon Jun 30 14:02:55 EDT 2025 Tue Jun 17 21:56:07 EDT 2025 Tue Jun 10 21:04:29 EDT 2025 Wed Feb 19 02:03:56 EST 2025 Tue Jul 01 00:37:18 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | liquid in situ transmission electron microscopy supercritical CO2 processing apoptosis RESS technique cell viability |
Language | English |
License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c521t-aadd858066fbac4747f035a9573fa7aa31572c3eba5bdfbf29bff56c99efbee03 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ORCID | 0000-0003-0269-6446 0000-0003-3414-6617 0000-0003-3450-6328 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/pharmaceutics16111471 |
PMID | 39598594 |
PQID | 3133269628 |
PQPubID | 2032349 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_e5a91634cce44c18b0130db59e558f0d pubmedcentral_primary_oai_pubmedcentral_nih_gov_11597759 proquest_miscellaneous_3133459065 proquest_journals_3133269628 gale_infotracmisc_A818468118 gale_infotracacademiconefile_A818468118 pubmed_primary_39598594 crossref_primary_10_3390_pharmaceutics16111471 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2024-11-01 |
PublicationDateYYYYMMDD | 2024-11-01 |
PublicationDate_xml | – month: 11 year: 2024 text: 2024-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland – name: Basel |
PublicationTitle | Pharmaceutics |
PublicationTitleAlternate | Pharmaceutics |
PublicationYear | 2024 |
Publisher | MDPI AG MDPI |
Publisher_xml | – name: MDPI AG – name: MDPI |
References | Tardito (ref_40) 2009; 284 Araujo (ref_31) 2014; 50 Tuschel (ref_32) 2014; 29 Pourmadadi (ref_12) 2022; 77 ref_34 Kelland (ref_5) 2007; 7 Brown (ref_8) 2019; 11 Palanikumar (ref_29) 2021; 12 Raghavan (ref_15) 2015; 47 Karbownik (ref_18) 2012; 16 Torres (ref_36) 2018; 122 Greene (ref_17) 1979; 36 ref_16 Kumar (ref_39) 2017; 2 Dasari (ref_9) 2014; 740 Jung (ref_20) 2001; 20 Sharma (ref_19) 2016; 109 Parhizkar (ref_37) 2020; 2 Koopman (ref_27) 1994; 84 Abe (ref_14) 2020; 6 Berridge (ref_24) 1993; 303 Palanikumar (ref_25) 2020; 59 Petsko (ref_4) 1995; 377 Amable (ref_10) 2016; 106 Brock (ref_11) 2012; 30 Sharma (ref_22) 2013; 282 Palanikumar (ref_30) 2023; 17 Ferlay (ref_1) 2021; 149 Astolfi (ref_13) 2013; 29 Siegel (ref_2) 2023; 73 ref_28 Elmore (ref_26) 2007; 35 Miller (ref_3) 2022; 72 Sharma (ref_21) 2020; 5 Munaweera (ref_33) 2015; 153 Barltrop (ref_23) 1991; 1 ref_7 Li (ref_38) 2014; 31 Lippard (ref_6) 1982; 218 Poy (ref_35) 2016; 88 |
References_xml | – volume: 36 start-page: 38 year: 1979 ident: ref_17 article-title: Stability of Cisplatin in Aqueous Solution publication-title: Am. J. Hosp. Pharm. – volume: 84 start-page: 1415 year: 1994 ident: ref_27 article-title: Annexin V for Flow Cytometric Detection of Phosphatidylserine Expression on B Cells Undergoing Apoptosis publication-title: Blood doi: 10.1182/blood.V84.5.1415.bloodjournal8451415 – volume: 109 start-page: 74 year: 2016 ident: ref_19 article-title: High Throughput RESS Processing of Sub-10nm Ibuprofen Nanoparticles publication-title: J. Supercrit. Fluids doi: 10.1016/j.supflu.2015.11.019 – volume: 12 start-page: 3962 year: 2021 ident: ref_29 article-title: Protein Mimetic Amyloid Inhibitor Potently Abrogates Cancer-Associated Mutant P53 Aggregation and Restores Tumor Suppressor Function publication-title: Nat. Commun. doi: 10.1038/s41467-021-23985-1 – volume: 149 start-page: 778 year: 2021 ident: ref_1 article-title: Cancer Statistics for the Year 2020: An Overview publication-title: Int. J. Cancer doi: 10.1002/ijc.33588 – volume: 284 start-page: 24306 year: 2009 ident: ref_40 article-title: The Thioxotriazole Copper (II) Complex A0 Induces Endoplasmic Reticulum Stress and Paraptotic Death in Human Cancer Cells publication-title: J. Biol. Chem. doi: 10.1074/jbc.M109.026583 – ident: ref_16 – volume: 88 start-page: 568 year: 2016 ident: ref_35 article-title: Preparation, Characterization, and Cytotoxic Effects of Liposomal Nanoparticles Containing Cisplatin: An in Vitro Study publication-title: Chem. Biol. Drug Des. doi: 10.1111/cbdd.12786 – volume: 2 start-page: 4632 year: 2017 ident: ref_39 article-title: Potent Anticancer Activity with High Selectivity of a Chiral Palladium N-Heterocyclic Carbene Complex publication-title: ACS Omega doi: 10.1021/acsomega.7b00688 – volume: 16 start-page: 435 year: 2012 ident: ref_18 article-title: The Physical and Chemical Stability of Cisplatin (Teva) in Concentrate and Diluted in Sodium Chloride 0.9% publication-title: Wspolczesna Onkol. doi: 10.5114/wo.2012.31775 – volume: 29 start-page: 14 year: 2014 ident: ref_32 article-title: Practical Group Theory and Raman Spectroscopy, Part I: Normal Vibrational Modes publication-title: Spectroscopy – volume: 73 start-page: 17 year: 2023 ident: ref_2 article-title: Cancer Statistics, 2023 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21763 – volume: 2 start-page: 1177 year: 2020 ident: ref_37 article-title: Enhanced Efficacy in Drug-Resistant Cancer Cells through Synergistic Nanoparticle Mediated Delivery of Cisplatin and Decitabine publication-title: Nanoscale Adv. doi: 10.1039/C9NA00684B – volume: 377 start-page: 580 year: 1995 ident: ref_4 article-title: Heavy Metal Revival publication-title: Nature doi: 10.1038/377580a0 – volume: 30 start-page: 2408 year: 2012 ident: ref_11 article-title: Platinum-Induced Ototoxicity in Children: A Consensus Review on Mechanisms, Predisposition, and Protection, Including a New International Society of Pediatric Oncology Boston Ototoxicity Scale publication-title: J. Clin. Oncol. doi: 10.1200/JCO.2011.39.1110 – volume: 7 start-page: 573 year: 2007 ident: ref_5 article-title: The Resurgence of Platinum-Based Cancer Chemotherapy publication-title: Nat. Rev. Cancer doi: 10.1038/nrc2167 – ident: ref_34 doi: 10.1002/9780470405840 – volume: 35 start-page: 495 year: 2007 ident: ref_26 article-title: Apoptosis: A Review of Programmed Cell Death publication-title: Toxicol. Pathol. doi: 10.1080/01926230701320337 – volume: 47 start-page: 322 year: 2015 ident: ref_15 article-title: Dimethyl Sulfoxide Inactivates the Anticancer Effect of Cisplatin against Human Myelogenous Leukemia Cell Lines in in Vitro Assays publication-title: Indian J. Pharmacol. doi: 10.4103/0253-7613.157132 – volume: 1 start-page: 611 year: 1991 ident: ref_23 article-title: 5-(3-Carboxymethoxyphenyl)-2-(4,5-Dimethylthiazolyl)-3-(4-Sulfophenyl)Te Trazolium, Inner Salt (MTS) and Related Analogs of 3-(4,5-Dimethylthiazolyl)-2,5-Diphenyltetrazolium Bromide (MTT) Reducing to Purple Water-Soluble Formazans As Cell-Viability Indica publication-title: Bioorganic Med. Chem. Lett. doi: 10.1016/S0960-894X(01)81162-8 – volume: 106 start-page: 27 year: 2016 ident: ref_10 article-title: Cisplatin Resistance and Opportunities for Precision Medicine publication-title: Pharmacol. Res. doi: 10.1016/j.phrs.2016.01.001 – volume: 72 start-page: 409 year: 2022 ident: ref_3 article-title: Cancer Treatment and Survivorship Statistics, 2022 publication-title: CA Cancer J. Clin. doi: 10.3322/caac.21731 – volume: 59 start-page: 2259 year: 2020 ident: ref_25 article-title: Hexokinase II-Derived Cell-Penetrating Peptide Mediates Delivery of MicroRNA Mimic for Cancer-Selective Cytotoxicity publication-title: Biochemistry doi: 10.1021/acs.biochem.0c00141 – volume: 20 start-page: 179 year: 2001 ident: ref_20 article-title: Particle Design Using Supercritical Fluids: Literature and Patent Survey publication-title: J. Supercrit. Fluids doi: 10.1016/S0896-8446(01)00064-X – ident: ref_28 doi: 10.1038/s42003-020-0817-4 – volume: 77 start-page: 103928 year: 2022 ident: ref_12 article-title: Cisplatin-Loaded Nanoformulations for Cancer Therapy: A Comprehensive Review publication-title: J. Drug Deliv. Sci. Technol. doi: 10.1016/j.jddst.2022.103928 – volume: 218 start-page: 1075 year: 1982 ident: ref_6 article-title: New Chemistry of an Old Molecule: Cis-[Pt(NH3) 2Cl2] publication-title: Science doi: 10.1126/science.6890712 – volume: 5 start-page: 4558 year: 2020 ident: ref_21 article-title: Supercritical CO2 Processing Generates Aqueous Cisplatin Solutions with Enhanced Cancer Specificity publication-title: ACS Omega doi: 10.1021/acsomega.9b03917 – volume: 303 start-page: 474 year: 1993 ident: ref_24 article-title: Characterization of the Cellular Reduction of 3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide (MTT): Subcellular Localization, Substrate Dependence, and Involvement of Mitochondrial Electron Transport in MTT Reduction publication-title: Arch. Biochem. Biophys. doi: 10.1006/abbi.1993.1311 – volume: 6 start-page: 3 year: 2020 ident: ref_14 article-title: Effect of Different Shielding Conditions on the Stability of Cisplatin publication-title: J. Pharm. Health Care Sci. doi: 10.1186/s40780-020-00163-x – volume: 50 start-page: 1223 year: 2014 ident: ref_31 article-title: Selective Extraction of Humic Acids from an Anthropogenic Amazonian Dark Earth and from a Chemically Oxidized Charcoal publication-title: Biol. Fertil. Soils doi: 10.1007/s00374-014-0940-9 – ident: ref_7 doi: 10.1016/j.bioorg.2019.102925 – volume: 17 start-page: 18979 year: 2023 ident: ref_30 article-title: PH-Responsive Upconversion Mesoporous Silica Nanospheres for Combined Multimodal Diagnostic Imaging and Targeted Photodynamic and Photothermal Cancer Therapy publication-title: ACS Nano doi: 10.1021/acsnano.3c04564 – volume: 740 start-page: 364 year: 2014 ident: ref_9 article-title: Cisplatin in Cancer Therapy: Molecular Mechanisms of Action publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2014.07.025 – volume: 153 start-page: 23 year: 2015 ident: ref_33 article-title: Nitric Oxide- and Cisplatin-Releasing Silica Nanoparticles for Use against Non-Small Cell Lung Cancer publication-title: J. Inorg. Biochem. doi: 10.1016/j.jinorgbio.2015.09.002 – volume: 282 start-page: 492 year: 2013 ident: ref_22 article-title: Influence of Annealing on Structural, Morphological, Compositional and Surface Properties of Magnetron Sputtered Nickel-Titanium Thin Films publication-title: Appl. Surf. Sci. doi: 10.1016/j.apsusc.2013.05.159 – volume: 11 start-page: 97 year: 2019 ident: ref_8 article-title: Cisplatin-Based Chemotherapy of Human Cancers publication-title: J. Cancer Sci. Ther. – volume: 122 start-page: 6934 year: 2018 ident: ref_36 article-title: Raman and Infrared Studies of Platinum-Based Drugs: Cisplatin, Carboplatin, Oxaliplatin, Nedaplatin, and Heptaplatin publication-title: J. Phys. Chem. A doi: 10.1021/acs.jpca.8b04023 – volume: 31 start-page: 86 year: 2014 ident: ref_38 article-title: Pharmacological Modulation of Cytotoxicity and Cellular Uptake of Anti-Cancer Drugs by PDE5 Inhibitors in Lung Cancer Cells publication-title: Pharm. Res. doi: 10.1007/s11095-013-1134-0 – volume: 29 start-page: 1285 year: 2013 ident: ref_13 article-title: Correlation of Adverse Effects of Cisplatin Administration in Patients Affected by Solid Tumours: A Retrospective Evaluation publication-title: Oncol. Rep. doi: 10.3892/or.2013.2279 |
SSID | ssj0000331839 |
Score | 2.3286483 |
Snippet | Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug,... The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug, with increased solubility... Background/Objectives: The primary goal of our research is to develop a process to prepare an aqueous dispersion of Cisplatin, an important anticancer drug,... |
SourceID | doaj pubmedcentral proquest gale pubmed crossref |
SourceType | Open Website Open Access Repository Aggregation Database Index Database |
StartPage | 1471 |
SubjectTerms | apoptosis Cancer Cancer therapies Carbon dioxide Care and treatment Cell research cell viability Cisplatin Cytotoxicity Drug delivery systems Ethylenediaminetetraacetic acid Leukemia liquid in situ transmission electron microscopy Raman spectroscopy RESS technique Side effects supercritical CO2 processing |
SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LT9wwELYQJy4VfZIClStV9EJKEj9iHwGBUKsiJEDiZtmOLVaC7IqUw_57ZuKwu1GRuHBM7CjxPL9xZsaE_AiyArdS81yVUeRcNkVuIbTOZSNRphtfRSxO_nsuz6757xtxs3LUF-aEpfbAiXAHQVhAMIx7Hzj3pcJ9u6JxQgchVCwatL7g81aCqd4GM5RVnUp2GLz8YHa73CLuAOZAHFCXI2fU9-z_3zKvuKZx2uSKHzrdJO8GAEkP04e_J2uh_UD2LtJ75_v0allQ1e3TPXqx7E09_0j-XM5bgHzdpKPTSC_DXczxt--9uwsNBUs7Tf1kHx_g8njSzTBTrqV9XgGF5yjyiw7FBZ_I9enJ1fFZPpynkHs8tiC3YMuUUAAyorOeQyARCwbkFTWLtraWlaKuPAvOCtdEFyvtYhTSax2iC6Fgn8l6O23DFqGxkM47QOfg_3mMXgXQZcYVZmE3umQZ-fVMWDNLbTMMhBvICfMiJzJyhORfTMau1_0NkAUzyIJ5TRYy8hOZZ1A3gUPeDiUG8M3Y5cocAjrhUkFMlZGd0UzQKT8efma_GXS6M7BAwLpaVjD8fTGMT2KeWhumj2kOFxpwXUa-JGlZLIlpoZXQPCNqJEejNY9H2slt3_EbYDvgdKG_vgWVtslGBcgsFVTukHWQq7ALyOqf-9Yr0RNAKSPs priority: 102 providerName: Directory of Open Access Journals – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB61cOml6rsptHKlil5ISeLH2qcKEAi1KloVkLhFsWPDSjTZEjjsv-9M4t0latVjYkexPQ9_M54ZA3zyqsBtZSJSnQeZClVnaYWmdapqRTxduyJQcvKPU3VyIb5dysvocOtiWOVSJ_aKum4d-cj3OBpThTKq0F_nv1O6NYpOV-MVGo9hE1WwRuNr8-DodPpz5WXJOPGsGVJ3OA5ib369dhV3CHfQHpjko02pr93_t4Z-sEWNwycf7EfHz-BpBJJsf6D8c3jkmxewMx3-u9hl5-vEqm6X7bDpukb14iV8P1s0CP26WcfawM78TUjp-PeXvfE1Q43bDnVl72_x8XDWzSlirmF9fAHD7xjRjcUkg1dwcXx0fniSxnsVUkfXF6QV6jQtNYKNYCsn0KAIGZeVkRMeqklV8VxOCse9raStgw2FsSFI5YzxwXqf8dew0bSNfwssZMo6iygdcYAIwWmPMs2Fpmjs2uQ8gS_LhS3nQ_mMEs0OokT5T0okcEDLv-pM1a_7F-3tVRmFqfQ4WMSRwjkvhMs1-XKz2krjpdQhqxP4TMQrSUaRQq6KqQY4Zqp2Ve4jShFKo22VwPaoJ8qWGzcvyV9G2e7KNScm8HHVTF9SvFrj2_uhj5AG8V0CbwZuWU2JG2m0NCIBPeKj0ZzHLc3suq_8jfAd8bo07_4_ri14UiD2GlImt2EDOca_R-x0Zz9EAfkD_tYcxw priority: 102 providerName: ProQuest |
Title | Synthesis of Self-Assembled Nanostructured Cisplatin Using the RESS Process |
URI | https://www.ncbi.nlm.nih.gov/pubmed/39598594 https://www.proquest.com/docview/3133269628 https://www.proquest.com/docview/3133459065 https://pubmed.ncbi.nlm.nih.gov/PMC11597759 https://doaj.org/article/e5a91634cce44c18b0130db59e558f0d |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9swED8heNnLtO9lY5WRJvZCWBrbif2AECAQ2gSqBpV4i2LHhkpd0jVDWv_73SVpSzR42GNiO7F9d77f2XdngM8uiVGtpCJUQy9DkRRRmKNpHSZFQjxd2NhTcPLFZXI-Ft9u5M0GLBMqdBNYP2ra0X1S4_l0_8-vxSEK_AFZnPjdr7O79e5vjQgGIT5FlW-hckpJVi86xN8szpyYWDdnzZruV4t5G9fz9Jd6GqtJ7P_v8v1Af_V9Kx8oq7MX8LxDmeyoZYuXsOHKV7A7av-72GPX66ireo_tstE6gfXiNXy_WpSIC-tJzSrPrtzUh3Q2_NNMXcFwOa7apLP3c3w8mdQzcqcrWeN8wLAdI6KyLgLhDYzPTq9PzsPu0oXQ0t0GYY4LnpIKkYg3uRVobfiIy1zLlPs8zXM-lGlsuTO5NIU3PtbGe5lYrZ03zkX8LWyWVeneA_NRYqxBCI8gQXhvlUOB50KRq3ahhzyA_eXEZrM2t0aGNglRInuUEgEc0_SvKlNq7OZFNb_NOknLHHYWQaaw1glhh4o2eqPCSO2kVD4qAvhCxMuIpZBCNu_iELDPlAorO0IIIxKFhlcA272aKHi2X7wkf7bk2wwHiIBYJzEW76yKqSU5s5Wuum_rCKkR_AXwruWW1ZC4llpJLQJQPT7qjblfUk7umrTgiO0RzEv94X-n9SM8ixGqtRGW27CJPOQ-IdT6bQawdXx6OfoxaLYqBo0o_QVqhSys |
linkProvider | Scholars Portal |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3Nb9MwFH8a3QEuiG8CA4wE47KwNLZT-4DQNjZ1dKsq1km7hdixWaWRlIUJ9Z_ib-S9Jm0XgbjtmNhJbL_Pn_PeM8Abl8RoVnoiVF0vQ5HkUZghtA6TPCGezm3sKTn5eJj0T8XnM3m2Br8XuTAUVrnQiXNFnZeW9si3OYKpONFJrD5Of4R0ahT9XV0coVGzxcDNfiFkqz4cfkL6vo3jg_3xXj9sThUILRXvDzOUaCUVmlpvMivQnfYRl5mWPe6zXpbxruzFljuTSZN742NtvJeJ1dp541zE8b23YF1whDIdWN_dH46-LHd1Ik4youtUIY6T3p6er7amK3SvEH_0ui0jOD8r4G-LcM0ktsM1r9m_g3twt3Fc2U7NafdhzRUPYHNUf3e2xcarRK5qi22y0aom9uwhDE5mBbqa1aRipWcn7sKH9Lv5u7lwOUMNX9Z1bK8u8XJvUk0pQq9g83gGhs8x4hPWJDU8gtMbWfHH0CnKwj0F5qPEWIOoAP0O4b1VDnUIF4qiv3Pd5QG8XyxsOq3LdaQIc4gS6T8pEcAuLf-yM1Xbnt8oL7-ljfCmDgeLfquw1glhu4r2jqPcSO2kVD7KA3hHxEtJJyCFbNakNuCYqbpWuoNekUgUYrkANlo9UZZtu3lB_rTRJVW64vwAXi-b6UmKjytceVX3EVKjPxnAk5pbllPiWmoltQhAtfioNed2SzE5n1caR7iA-EDqZ_8f1yu43R8fH6VHh8PBc7gTo99Xp2tuQAe5x71Av-2nedkIC4OvNy2ffwDPxVxy |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFD4anYR4QdwJDDASjJdlTWI7sR8Q2q3aKFQV26S9hdixWaWRlIUJ9a_x6zjOpV0E4m2PbZzW8bl9n3POMcAbE0cYVhLmi9Byn8V54GdIrf04j51O5zqyrjj58yQ-PGUfz_jZGvzuamFcWmXnE2tHnZfa7ZEPKZKpKJZxJIa2TYuY7o8-zH_47gQp96a1O06jUZGxWfxC-la9P9pHWb-NotHByd6h354w4GvXyN_P0LoFFxh2rco0Q2htA8ozyRNqsyTLaMiTSFOjMq5yq2wklbU81lIaq4wJKP7uLVhPkBUFA1jfPZhMvyx3eALq7EU2ZUMUF2A4P19tU1cItZCLJGEvINbnBvwdHa6Fx37q5rVYOLoHd1sQS3YarbsPa6Z4AJvT5n8XW-RkVdRVbZFNMl31x148hPHxokDYWc0qUlpybC6s7149f1cXJifo7cump-3VJX7cm1Vzl61XkDq3geB9xOkMaQscHsHpjaz4YxgUZWGeArFBrLRChoAYhFmrhUF_QplwmeC5DKkH293CpvOmdUeKlMdJIv2nJDzYdcu_HOw6b9dflJff0taQU4OTRQzLtDaM6VC4feQgV1wazoUNcg_eOeGlzj-ghHTWljngnF2nrXQHERKLBfI6DzZ6I9Gudf9yJ_609StVurICD14vL7s7Xa5cYcqrZgzjErGlB08abVk-EpVcCi6ZB6KnR71n7l8pZud113GkDsgVuHz2_3m9gttol-mno8n4OdyJEAI2lZsbMEDlMS8Qwv1UL1tbIfD1ps3zD6srYKc |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Synthesis+of+Self-Assembled+Nanostructured+Cisplatin+Using+the+RESS+Process&rft.jtitle=Pharmaceutics&rft.au=Sharma%2C+Sudhir+Kumar&rft.au=Palanikumar%2C+Loganathan&rft.au=Pasricha%2C+Renu&rft.au=Prakasam%2C+Thirumurugan&rft.date=2024-11-01&rft.issn=1999-4923&rft.eissn=1999-4923&rft.volume=16&rft.issue=11&rft.spage=1471&rft_id=info:doi/10.3390%2Fpharmaceutics16111471&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_pharmaceutics16111471 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon |